The PPAR alpha agonist gemfibrozil is an ineffective treatment for spinal cord injured mice

Akshata Almad, A. Todd Lash, Ping Wei, Amy E. Lovett-Racke, Dana M. McTigue

Research output: Contribution to journalArticle

Abstract

Peroxisome Proliferator Activated Receptor (PPAR)-α is a key regulator of lipid metabolism and recent studies reveal it also regulates inflammation in several different disease models. Gemfibrozil, an agonist of PPAR-α, is a FDA approved drug for hyperlipidemia and has been shown to inhibit clinical signs in a rodent model of multiple sclerosis. Since many studies have shown improved outcome from spinal cord injury (SCI) by anti-inflammatory and neuroprotective agents, we tested the efficacy of oral gemfibrozil given before or after SCI for promoting tissue preservation and behavioral recovery after spinal contusion injury in mice. Unfortunately, the results were contrary to our hypothesis; in our first attempt, gemfibrozil treatment exacerbated locomotor deficits and increased tissue pathology after SCI. In subsequent experiments, the behavioral effects were not replicated but histological outcomes again were worse. We also tested the efficacy of a different PPAR-α agonist, fenofibrate, which also modulates immune responses and is beneficial in several neurodegenerative disease models. Fenofibrate treatment did not improve recovery, although there was a slight trend for a modest increase in histological tissue sparing. Based on our results, we conclude that PPAR-α agonists yield either no effect or worsen recovery from spinal cord injury, at least at the doses and the time points of drug delivery tested here. Further, patients sustaining spinal cord injury while taking gemfibrozil might be prone to exacerbated tissue damage.

Original languageEnglish (US)
Pages (from-to)309-317
Number of pages9
JournalExperimental Neurology
Volume232
Issue number2
DOIs
StatePublished - Dec 1 2011
Externally publishedYes

Fingerprint

Gemfibrozil
PPAR alpha
Spinal Cord Injuries
Peroxisome Proliferator-Activated Receptors
Spinal Cord
Fenofibrate
Tissue Preservation
Therapeutics
Spinal Injuries
Contusions
Neuroprotective Agents
Hyperlipidemias
Lipid Metabolism
Neurodegenerative Diseases
Pharmaceutical Preparations
Multiple Sclerosis
Rodentia
Anti-Inflammatory Agents
Pathology
Inflammation

Keywords

  • Inflammation
  • Locomotor recovery
  • Macrophage
  • Myelin
  • Neuroprotection
  • PPAR alpha
  • Spinal cord injury
  • T cells
  • White matter sparing

ASJC Scopus subject areas

  • Neurology
  • Developmental Neuroscience

Cite this

The PPAR alpha agonist gemfibrozil is an ineffective treatment for spinal cord injured mice. / Almad, Akshata; Lash, A. Todd; Wei, Ping; Lovett-Racke, Amy E.; McTigue, Dana M.

In: Experimental Neurology, Vol. 232, No. 2, 01.12.2011, p. 309-317.

Research output: Contribution to journalArticle

Almad, Akshata ; Lash, A. Todd ; Wei, Ping ; Lovett-Racke, Amy E. ; McTigue, Dana M. / The PPAR alpha agonist gemfibrozil is an ineffective treatment for spinal cord injured mice. In: Experimental Neurology. 2011 ; Vol. 232, No. 2. pp. 309-317.
@article{b4354564a0b84464b1bb2722c3c8dcfb,
title = "The PPAR alpha agonist gemfibrozil is an ineffective treatment for spinal cord injured mice",
abstract = "Peroxisome Proliferator Activated Receptor (PPAR)-α is a key regulator of lipid metabolism and recent studies reveal it also regulates inflammation in several different disease models. Gemfibrozil, an agonist of PPAR-α, is a FDA approved drug for hyperlipidemia and has been shown to inhibit clinical signs in a rodent model of multiple sclerosis. Since many studies have shown improved outcome from spinal cord injury (SCI) by anti-inflammatory and neuroprotective agents, we tested the efficacy of oral gemfibrozil given before or after SCI for promoting tissue preservation and behavioral recovery after spinal contusion injury in mice. Unfortunately, the results were contrary to our hypothesis; in our first attempt, gemfibrozil treatment exacerbated locomotor deficits and increased tissue pathology after SCI. In subsequent experiments, the behavioral effects were not replicated but histological outcomes again were worse. We also tested the efficacy of a different PPAR-α agonist, fenofibrate, which also modulates immune responses and is beneficial in several neurodegenerative disease models. Fenofibrate treatment did not improve recovery, although there was a slight trend for a modest increase in histological tissue sparing. Based on our results, we conclude that PPAR-α agonists yield either no effect or worsen recovery from spinal cord injury, at least at the doses and the time points of drug delivery tested here. Further, patients sustaining spinal cord injury while taking gemfibrozil might be prone to exacerbated tissue damage.",
keywords = "Inflammation, Locomotor recovery, Macrophage, Myelin, Neuroprotection, PPAR alpha, Spinal cord injury, T cells, White matter sparing",
author = "Akshata Almad and Lash, {A. Todd} and Ping Wei and Lovett-Racke, {Amy E.} and McTigue, {Dana M.}",
year = "2011",
month = "12",
day = "1",
doi = "10.1016/j.expneurol.2011.09.023",
language = "English (US)",
volume = "232",
pages = "309--317",
journal = "Experimental Neurology",
issn = "0014-4886",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - The PPAR alpha agonist gemfibrozil is an ineffective treatment for spinal cord injured mice

AU - Almad, Akshata

AU - Lash, A. Todd

AU - Wei, Ping

AU - Lovett-Racke, Amy E.

AU - McTigue, Dana M.

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Peroxisome Proliferator Activated Receptor (PPAR)-α is a key regulator of lipid metabolism and recent studies reveal it also regulates inflammation in several different disease models. Gemfibrozil, an agonist of PPAR-α, is a FDA approved drug for hyperlipidemia and has been shown to inhibit clinical signs in a rodent model of multiple sclerosis. Since many studies have shown improved outcome from spinal cord injury (SCI) by anti-inflammatory and neuroprotective agents, we tested the efficacy of oral gemfibrozil given before or after SCI for promoting tissue preservation and behavioral recovery after spinal contusion injury in mice. Unfortunately, the results were contrary to our hypothesis; in our first attempt, gemfibrozil treatment exacerbated locomotor deficits and increased tissue pathology after SCI. In subsequent experiments, the behavioral effects were not replicated but histological outcomes again were worse. We also tested the efficacy of a different PPAR-α agonist, fenofibrate, which also modulates immune responses and is beneficial in several neurodegenerative disease models. Fenofibrate treatment did not improve recovery, although there was a slight trend for a modest increase in histological tissue sparing. Based on our results, we conclude that PPAR-α agonists yield either no effect or worsen recovery from spinal cord injury, at least at the doses and the time points of drug delivery tested here. Further, patients sustaining spinal cord injury while taking gemfibrozil might be prone to exacerbated tissue damage.

AB - Peroxisome Proliferator Activated Receptor (PPAR)-α is a key regulator of lipid metabolism and recent studies reveal it also regulates inflammation in several different disease models. Gemfibrozil, an agonist of PPAR-α, is a FDA approved drug for hyperlipidemia and has been shown to inhibit clinical signs in a rodent model of multiple sclerosis. Since many studies have shown improved outcome from spinal cord injury (SCI) by anti-inflammatory and neuroprotective agents, we tested the efficacy of oral gemfibrozil given before or after SCI for promoting tissue preservation and behavioral recovery after spinal contusion injury in mice. Unfortunately, the results were contrary to our hypothesis; in our first attempt, gemfibrozil treatment exacerbated locomotor deficits and increased tissue pathology after SCI. In subsequent experiments, the behavioral effects were not replicated but histological outcomes again were worse. We also tested the efficacy of a different PPAR-α agonist, fenofibrate, which also modulates immune responses and is beneficial in several neurodegenerative disease models. Fenofibrate treatment did not improve recovery, although there was a slight trend for a modest increase in histological tissue sparing. Based on our results, we conclude that PPAR-α agonists yield either no effect or worsen recovery from spinal cord injury, at least at the doses and the time points of drug delivery tested here. Further, patients sustaining spinal cord injury while taking gemfibrozil might be prone to exacerbated tissue damage.

KW - Inflammation

KW - Locomotor recovery

KW - Macrophage

KW - Myelin

KW - Neuroprotection

KW - PPAR alpha

KW - Spinal cord injury

KW - T cells

KW - White matter sparing

UR - http://www.scopus.com/inward/record.url?scp=80055022344&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80055022344&partnerID=8YFLogxK

U2 - 10.1016/j.expneurol.2011.09.023

DO - 10.1016/j.expneurol.2011.09.023

M3 - Article

C2 - 21963672

AN - SCOPUS:80055022344

VL - 232

SP - 309

EP - 317

JO - Experimental Neurology

JF - Experimental Neurology

SN - 0014-4886

IS - 2

ER -